Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
Free accessResearch articleFirst published online June, 2007
Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
Roux-en-Y bypass surgery is increasingly used for treatment of gross obesity due to the general inability of lifestyle change and existing drug treatments to counter the obesity epidemic. This common form of bariatric surgery involves bypass of the small intestine with significant reduction of body of weight that is independent of malabsorption. Strikingly, obesity-related diabetes is also cured by the procedure but prior to body weight loss. This is due to rapid improvement of insulin resistance and associated pancreatic beta-cell function. Several hypotheses have been proposed to account for this phenomenon, but the most attractive concerns surgical ablation of gastric inhibitory polypetide (GIP)-secreting intestinal K-cells. Thus, circulating GIP levels are decreased after Roux-en-Y bypass surgery and GIP is known to play a key role in lipid metabolism and fat deposition. Further, both genetic and chemical ablation of GIP in animal models has been shown to protect against obesity and associated metabolic disturbances. These observations in animals and man suggest that GIP receptor antagonism may afford an alternative therapeutic option for treatment of obesity-diabetes.
1. Sattar N, Lean M (Eds). ABC of obesity. BMJ2006;333:parts over 640–1111.
2.
2. World Health Organization. Facts sheet on diabetes, obesity and overweight. Geneva: World Health Organization, 2006.
3.
3. Lean M, Finer N.ABC of obesity. Management: part II - drugs. BMJ2006;333:794–7.
4.
4. Bailey CJ.Drugs on the horizon for diabesity. Curr Diab Rep2005;5:353–9.
5.
5. Blackburn GL.Solutions in weight control: lessons from gastric surgery. Am J Clin Nutr2005;82(suppl 1):248S–252S.
6.
6. Kral JG.ABC of obesity. Management: Part III - surgery. BMJ2006;333:900–03.
7.
7. National Institute for Health and Clinical Excellence (NICE).Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE Clinical Guideline2006;43:1–84.
8.
8. Kenler HA, Brolin RE, Cody RP.Changes in eating behaviour after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr1990;52:87–92.
9.
9. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJB.Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg2006;93:210–15.
10.
10. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HR.Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type II diabetes mellitus. American Surgeon2004;70:1–5.
11.
11. Rubino F, Gagner M, Gentileschi P. et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg2004;240:236–42.
12.
12. Guidone C, Manco M, Valera-Mora E et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes2006;55:2025–31.
13.
13. Mari A, Manco M, Guidone C. et al. Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia2006;49:2136–43.
14.
14. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK.Restoration of euglycemia and normal insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes2003;52:1098–103.
15.
15. Poitout V, Robertson RP.Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology2002;143:339–42.
16.
16. Le Roux CW, Alywin S, Batterham RL. et al. Gut hormone profiles following bariatric surgery favour an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg2006;243:108–14.
17.
17. Gumbs AA, Modlin IM, Ballantyne GH.Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obesity Surgery2005;15:462–73.
18.
18. Drucker DJ.The role of gut hormones in glucose homeostasis. J Clin Invest2007;117:24–32.
19.
19. Miyawaki K, Yamada Y, Ban N. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med2002;8:738–42.
20.
20. Gault VA, Irwin N, Green BD. et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes2005;54:2436–46.
21.
21. Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y.Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes2006:55(suppl 2):S86–S91.
22.
22. Zhou H, Yamada Y, Tsukiyama K. et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun2005;335:937–42.
23.
23. Hansotia T, Maida A, Flock G. et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight and energy expenditure. J Clin Invest2007;117:143–52.
24.
24. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR.Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia2007;50:1752–62. Epub 2007 Jun 9.
25.
25. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.Preserved incretin activity of glucagon-like peptide 1 (7–36)amide but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest1993;91:301–07.
26.
26. Irwin N, McClean PL, O'harte FP, Gault VA, Harriott P, Flatt PR.Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of Diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia2007;50:1532–40. Epub 2007 May 8.
